Chronic Kidney Diseases, Peritoneal Dialysis, Hemodialysis
Conditions
Keywords
chronic kidney disease, peritoneal dialysis, curcumin, hemodialysis
Brief summary
The objective of this study is to assess whether supplementation with curcumin could modulate the intestinal microbiota, reducing levels of inflammatory markers of oxidative stress, uremic toxins and inflammasome, in patients with chronic kidney disease in peritoneal dialysis.
Detailed description
Curcumin is a chemical compound of the curcuminoids class found in the root of Curcuma (Curcuma longa), and due to its potential antioxidant and anti-inflammatory, has been suggested as a nutritional strategy to reduce oxidative stress and inflammation present in several chronic diseases. Although it is a promising therapy, there are no studies evaluating the effects of curcumin in patients with chronic kidney disease (CKD) in peritoneal dialysis (PD). The aim of this study is to evaluate the effect of curcumin supplementation on inflammatory markers and oxidative stress in patients with CKD in PD. Methods: This is a longitudinal randomized clinical double-blind crossover study, with a washout period and placebo-controlled, where patients will be randomized into two groups: Turmeric and Placebo. After the 12-week supplementation period, a washout (12 weeks) will be performed for subsequent crossover of the patients. Mononuclear cells will be extracted from whole blood and the expression of m ribonucleic acid from transcription factors (Nrf2 and NF-kB), antioxidant enzymes (NQO1, HO-1), as well as NLRP3 inflammasome will be analyzed by real-time Polymerase Chain Reaction and protein expression by western blotting. Inflammatory cytokine levels will be assessed by ELISA, also, plasma levels of TBARS, routine laboratory parameters, as well as food intake and nutritional status.
Interventions
DIETARY_SUPPLEMENTCurcumin supplementation
The patients will receive 3 capsules per day containing 500mg of curcumin for 4 weeks
Sponsors
Universidade Federal Fluminense
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Clinical diagnosis of Chronic Kidney Disease * Peritoneal dialysis patients for more than 6 months * Aged from 18 to 60 years * Must be able to swallow tablets
Exclusion criteria
* Patients pregnant * Smokers * Using antibiotics in the last 3 months * Using antioxidant supplements in the last 3 months * Usual intake of turmeric * Usual intake Autoimmune * Clinical diagnosis of infectious diseases * Clinical diagnosis of Cancer * Clinical diagnosis of AIDS
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Antioxidants and anti-inflammatory biomarkers | 4 weeks | Get blood samples to evaluate the supplementation effects in antioxidants biomarkers- nuclear receptor factor 2 (Nrf2), glutathione peroxidase (GPx), heme oxygenase-1 (HO-1) |
| Inflammatory biomarkers | 4 weeks | Get blood samples to evaluate the supplementation effects in inflammatory biomarkers- factor nuclear kappaB, interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), PCR, IL-18, TBARS, Inflammasome. |
Countries
Brazil
Outcome results
None listed